民生证券股份有限公司 关于广州洁特生物过滤股份有限公司 2023 年半年度持续督导跟踪报告 根据《证券发行上市保荐业务管理办法》（以下简称"《保荐办法》"）、 《上海证券交易所科创板股票上市规则》（以下简称"《上市规则》"）等有 关法规和规范性文件的要求，民生证券股份有限公司（以下简称"保荐机构"） 作为广州洁特生物过滤股份有限公司（以下简称"洁特生物"、"上市公司"、 "公司"）首次公开发行股票并在科创板上市及 2022 年向不特定对象发行可转 换公司债券并在科创板上市的保荐机构对上市公司进行持续督导，并出具本持 续督导跟踪报告： 一、持续督导工作情况 | 序号 | 工作内容 | 持续督导工作情况 | | --- | --- | --- | | 1 | | 保荐机构已建立健全并有效执 | | | 建立健全并有效执行持续督导工作制度，并针对 | 行持续督导工作制度，并针对 | | | 具体的持续督导工作制定相应的工作计划 | 具体的持续督导工作制定相应 | | | | 的工作计划 | | 2 | 根据中国证监会相关规定，在持续督导工作开始 前，与上市公司或相关当事人签署持续督导协 | 保荐机构已与上市公司签署 ...

1、 案件所处的诉讼阶段：一审已判决 2、 上市公司所处的当事人地位：公司全资子公司广州拜费尔空气净化材料有 限公司为本诉被告一、反诉原告；公司为本诉被告二 3、 涉案的金额：本诉涉案的金额：人民币 12,199,190 元，其中返还货款 9,300,000 元，赔偿经济损失 2,899,190 元；反诉涉案的金额：拜费尔请求法 院判令金棒公司继续履行拜费尔与反诉被告金棒公司签署的《销售合同》 及其《补充协议》。 4、 判决结果：支持解除涉案的两份《销售合同》及《补充协议》；支持子公 司拜费尔向原告（反诉被告）金棒公司返还货款 775 万元及利息；公司对 前述债务承担连带清偿责任；驳回原告（反诉被告）金棒公司其他诉讼请 求，驳回子公司拜费尔全部诉讼请求。 5、 是否会对上市公司损益产生负面影响：涉案金额合计 12,199,190 元，占公 司 2022 年度营业收入比例为 2.00%，所占比例较小，公司预计本次诉讼不 会对公司正常生产经营造成重大不利影响。2020 年公司已对该买卖合同确 认了 145 万元的收入，利息和诉讼相关费用损失合计约 97 万元（暂按截止 至公告日测算，具体以实际付清之日为准）。本次 ...

| 证券代码：688026 | 证券简称：洁特生物 公告编号：2023-032 | | --- | --- | | 转债代码：118010 | 转债简称：洁特转债 | 广州洁特生物过滤股份有限公司 关于召开 2022 年年度业绩说明会暨现金分红说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ● 投资者可于 2023 年 5 月 8 日(星期一)16:00 前登录上证路演中心网站首 页点击"提问预征集"栏目或通过公司邮箱 jetzqb@jetbiofil.com 进行提问。公司 将在说明会上对投资者普遍关注的问题进行回答。 广州洁特生物过滤股份有限公司（以下简称"公司"）已于 2023 年 4 月 28 日发布公司 2022 年年度报告及《关于 2022 年年度利润分配预案的公告》。为便 于广大投资者更全面深入地了解公司 2022 年年度经营成果、财务状况，公司计 划于 2023 年 5 月 9 日下午 13:00-14:00 举行 2022 年年度业绩说明会暨现金分红 说明会，就投资者关心的问 ...

Financial Performance - The company's operating revenue for 2022 was approximately ¥609.82 million, a decrease of 28.73% compared to ¥855.66 million in 2021[24]. - The net profit attributable to shareholders for 2022 was approximately ¥87.71 million, down 48.75% from ¥171.16 million in 2021[24]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was approximately ¥75.49 million, a decline of 56.36% from ¥173.00 million in 2021[24]. - The net cash flow from operating activities for 2022 was approximately ¥166.19 million, a decrease of 24.93% compared to ¥221.38 million in 2021[24]. - The total revenue for the reporting period was 609.82 million yuan, a year-on-year decrease of 28.73%[40]. - The gross margin for consumables was 32.01%, a decrease of 9.73 percentage points compared to the previous year[107]. - The company's total revenue decreased by 28.75% year-on-year, primarily due to high base effects from last year's significant sales of products like pipette tips and a decline in overseas market demand[106]. Profit Distribution - The proposed profit distribution plan for 2022 includes a cash dividend of 0.7124 CNY per 10 shares, totaling 10,000,000 CNY, which accounts for 11.40% of the net profit attributable to shareholders[5]. - The profit distribution plan requires approval from the shareholders' meeting[5]. - The profit distribution policy emphasizes a minimum cash dividend of 10% of the distributable profit, with higher percentages based on the company's development stage and capital expenditure plans[180]. - The company has established a differentiated cash dividend policy, with a minimum of 80% cash distribution for mature stages without major expenditures[180]. Research and Development - The company applied for 49 patents during the reporting period, including 5 invention patents and 7 utility model patents[39]. - The company achieved a total of 190 authorized patents by the end of the reporting period, including 33 invention patents and 94 utility model patents[39]. - The total R&D investment for the year was approximately ¥37.34 million, a decrease of 14.83% compared to the previous year, with R&D investment accounting for 6.12% of operating income[67]. - The company is developing a temperature-responsive cell culture surface, which aims to improve cell harvesting efficiency without damaging cells[71]. - The company is focusing on upgrading its product materials to meet higher biological safety standards, including the use of medical-grade and biodegradable materials[55]. Market and Competition - The company anticipates facing intensified competition and a slow recovery in overall demand in the short term, prompting adjustments in its operational strategies[44]. - The global market for disposable plastic consumables in biological laboratories reached $11.01 billion in 2018, with a compound annual growth rate (CAGR) of 5.3% from 2014 to 2018, and is expected to grow to $13.75 billion by 2023 at a CAGR of 4.5%[50]. - The Chinese market for disposable plastic consumables in biological laboratories grew from RMB 4.28 billion in 2014 to RMB 7.57 billion in 2018, achieving a CAGR of 15.3%, and is projected to reach RMB 15.08 billion by 2023[51]. - The company has established itself as a leading player in the domestic market for disposable plastic consumables in biological laboratories, despite facing significant competition from international brands[54]. Corporate Governance - The company does not have any special arrangements for corporate governance[8]. - The company has not violated any decision-making procedures for providing guarantees[8]. - The company has implemented a comprehensive quality management system in accordance with international standards, ensuring product reliability and safety[86]. - The company continues to enhance its governance structure and investor relations, ensuring transparency and protecting shareholder rights[200]. Risks and Challenges - The company has detailed potential risks in the annual report, which can be found in the section "Management Discussion and Analysis" under "Risk Factors"[3]. - The company is exposed to risks from raw material price fluctuations, particularly for plastics derived from petroleum[96]. - The company faced risks related to new product market promotion, with potential delays in achieving large-scale sales impacting profitability[92]. - The domestic market expansion remains challenging due to the dominance of imported brands, which may hinder the company's market share growth[93]. Employee and Management Compensation - Total remuneration for directors, supervisors, and senior management amounted to RMB 5.8685 million[164]. - The company has implemented stock incentive plans for several key personnel, indicating a focus on aligning management interests with shareholder value[156]. - The total compensation for senior management during the reporting period amounted to 41.39 million Yuan, with a total of 16.92 million Yuan in performance-related pay[195]. Financial Position - The total assets at the end of 2022 were approximately ¥1.61 billion, an increase of 35.99% from ¥1.18 billion at the end of 2021[24]. - The net assets attributable to shareholders at the end of 2022 were approximately ¥1.14 billion, up 17.24% from ¥971.82 million at the end of 2021[24]. - The company's cash and cash equivalents at the end of the period were 598,881,869.58 RMB, an increase of 127.31% compared to the previous period[128]. - The company has a total long-term loan of CNY 19,850,000, with a repayment rate of 1.68%[129]. Strategic Initiatives - The company aims to expand its market share in the domestic and international markets over the next three to five years, focusing on the biotechnological research tools sector[144]. - The company plans to penetrate the medical consumables and medical devices industry, leveraging its core technology in cell culture and disposable plastic consumables[144]. - The company is committed to fulfilling its social responsibilities, focusing on sustainable development and stakeholder interests[200].

Financial Performance - The company's operating revenue for Q1 2023 was ¥74,281,810.80, representing a decrease of 60.98% compared to the same period last year[2] - The net profit attributable to shareholders was -¥8,797,295.17, a decline of 121.45% year-over-year[2] - Total revenue for Q1 2023 was CNY 74,281,810.80, a decrease of 61.0% compared to CNY 190,362,813.69 in Q1 2022[16] - The net loss for Q1 2023 was CNY 8,741,237.41, compared to a net profit of CNY 41,015,898.04 in Q1 2022, indicating a significant decline in profitability[17] - Operating profit for Q1 2023 was CNY -8,164,495.07, a decrease from CNY 47,660,359.74 in the same period last year[17] Cash Flow - The net cash flow from operating activities increased by 57.71% to ¥32,825,677.22[2] - In Q1 2023, the cash inflow from operating activities was $113,846,781.35, a decrease of 46.4% compared to $212,236,160.54 in Q1 2022[21] - The net cash outflow from operating activities was $81,021,104.13, down from $191,422,525.03 in the same period last year, resulting in a net cash flow from operating activities of $32,825,677.22, an increase of 57.5% year-over-year[22] - The cash inflow from investment activities totaled $70,357,044.95, while cash outflow was $114,910,710.57, leading to a net cash flow from investment activities of -$44,553,665.62, an improvement from -$77,178,782.19 in Q1 2022[22] - The cash flow from financing activities resulted in a net outflow of $1,763,127.43, compared to a net outflow of $2,469,321.10 in the previous year, indicating a 28.5% reduction in cash outflow[22] Assets and Liabilities - The total assets at the end of Q1 2023 were ¥1,582,523,905.09, a decrease of 1.42% from the end of the previous year[3] - The company's total assets as of Q1 2023 were CNY 1,582,523,905.09, slightly down from CNY 1,605,340,593.15 in Q1 2022[15] - Total liabilities decreased to CNY 451,130,703.31 in Q1 2023 from CNY 465,208,287.98 in Q1 2022, a reduction of 3.0%[15] - The total current assets amounted to ¥808.87 million, down from ¥848.62 million at the end of 2022[13] - The total non-current assets amounted to CNY 773,656,320.74 in Q1 2023, compared to CNY 756,721,497.98 in Q1 2022, showing an increase of 2.2%[15] Shareholder Information - The total number of common shareholders at the end of the reporting period was 7,029[10] - The largest shareholder, Yuan Jianhua, holds 30.98% of the shares, totaling 43,484,584 shares[10] Research and Development - Research and development expenses totaled ¥6,854,150.51, accounting for 9.23% of operating revenue, which is an increase of 4.14 percentage points[2] - Research and development expenses for Q1 2023 were CNY 6,854,150.51, down from CNY 9,684,707.76 in Q1 2022, a decrease of 29.0%[17] Market and Product Development - The company has no significant new product launches or technological developments reported in the current quarter[12] - There are no major market expansions or acquisitions mentioned in the latest report[12] - The company has not provided specific future guidance or performance outlook in the current report[12] Revenue Breakdown - Revenue from consumables was ¥72,990,100, a year-over-year decline of 61.16%[6] - Revenue from international customers decreased by 67.19% to ¥42,650,000, with specific declines in pipette tips and suction heads of 80.22% and 74.20%, respectively[7] - The comprehensive gross margin for consumable products dropped to 23.41%, down from 38.57% in the same period last year[8] Cash and Equivalents - The company's cash and cash equivalents as of March 31, 2023, were approximately ¥579.85 million, a decrease from ¥598.88 million at the end of 2022[13] - The total cash and cash equivalents at the end of Q1 2023 were $295,490,898.71, compared to $202,944,762.76 at the end of Q1 2022, reflecting a year-over-year increase of 45.5%[22] Other Financial Metrics - The issuance of convertible bonds in June 2022 resulted in an additional interest expense of ¥6,060,000 for the current period[8] - The company reported a basic and diluted earnings per share of CNY -0.06 for Q1 2023, compared to CNY 0.29 in Q1 2022[18] - Accounts receivable decreased to ¥85.85 million from ¥104.95 million year-over-year[13] - Inventory increased slightly to ¥126.04 million from ¥124.81 million at the end of 2022[13] - The company has not adopted new accounting standards for the current year, maintaining consistency in financial reporting[23]

1 证券代码：688026 证券简称：洁特生物 广州洁特生物过滤股份有限公司 投资者关系活动记录表 | --- | --- | --- | --- | |---------------------|--------------------------|------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | 投资者关系活动 类别 | √特定对象调研 | □媒体采访 √业绩说明会 \n□现场参观 □其他 | □分析师会议 □新闻发布会 \n□路演活动 | | | | | 中泰证券资管、上海楹联投资、长城财富、博远基金、邦政资产、博 | | | | | 道基金、工银瑞信基金、招商证券、英大证券自营、敦和资产、凯丰 投资、华宝 ...

证券代码：688026 证券简称：洁特生物 公告编号：2022-065 转债代码：118010 转债简称：洁特转债 广州洁特生物过滤股份有限公司 关于参加 2022 年广东辖区上市公司 投资者网上集体接待日活动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 为进一步加强与投资者的互动交流，广州洁特生物过滤股份有限公司（以下 简称"公司"）将参加由广东证监局、广东上市公司协会、深圳市全景网络有限 公司共同举办的"2022 年广东辖区上市公司投资者网上集体接待日活动"，现 将有关事项公告如下： 本次集体接待日活动时间为 2022 年 9 月 22 日（星期四）15:50 至 16:50，活 动平台为深圳市全景网络有限公司提供的互联网平台。投资者可以登陆"全景路 演"网站（http://rs.p5w.net）参与公司本次投资者集体接待日活动。 届时公司高管将在线通过网络在线问答互动的形式，与投资者就公司业绩、 公司治理、发展战略、经营情况等投资者关注的问题进行沟通与交流。 欢迎广大投资者积极参与。 特此公告。 广州洁特生 ...

Financial Performance - The company reported a significant increase in revenue for the first half of 2022, with a total revenue of 500 million RMB, representing a 25% year-over-year growth[1]. - The company's basic earnings per share for the first half of 2022 was CNY 0.70, a decrease of 24.73% compared to CNY 0.93 in the same period last year[18]. - The company's revenue decreased by 12.57% year-on-year, primarily due to high revenue from pandemic-related products in the previous year[18]. - The company's net profit attributable to shareholders decreased by 24.66% year-on-year to CNY 69,965,226.46, while the net profit excluding non-recurring gains and losses fell by 31.53% to CNY 67,622,215.83, primarily due to a decline in revenue from pandemic-related products[19]. - The company's total revenue for the reporting period was CNY 349,702,873.23, representing a 12.57% decrease compared to CNY 399,962,167.63 in the previous year[19]. - The company achieved operating revenue of 349.70 million, a year-on-year decrease of 12.57% due to high base effects from the previous year and pandemic-related impacts[54]. - The company reported a total comprehensive income of CNY 72,161,987.20 for the first half of 2022, compared to CNY 108,316,644.50 in the same period of the previous year, indicating a decrease of about 33.33%[190]. Research and Development - Research and development investments increased by 30%, focusing on innovative filtration technologies[1]. - The company's R&D investment accounted for 5.71% of operating income, an increase of 1.72 percentage points compared to the previous year[18]. - The company is focusing on expanding its biological culture consumables segment, which showed significant growth[18]. - The company continues to prioritize R&D to enhance product offerings and market competitiveness[18]. - The company increased its R&D investment to approximately ¥19.98 million, a 25.20% increase compared to ¥15.96 million in the same period last year[33]. - The company applied for 25 patents and obtained 13 patents during the reporting period, bringing the total to 248 applications and 161 granted patents[31]. - The company has developed key technologies such as super-hydrophilic cell culture surfaces and 3D cell culture scaffolds, which are at the leading level in the domestic industry[47]. Market Expansion - The company is expanding its market presence in Southeast Asia, targeting a 10% market share by the end of 2023[1]. - The company is focused on developing new products such as large-capacity cell culture flasks and ultrafiltration centrifuge tubes to meet market demands in cell therapy and biopharmaceuticals[25]. - The company is actively developing new products, including large-capacity cell culture flasks and ultrafiltration centrifuge tubes, to meet market demands in cell therapy and vaccine development[54]. - The company is enhancing its domestic marketing network to improve sales service and increase market penetration among domestic customers[54]. Financial Position - The company has maintained a strong cash position, with cash reserves of 200 million RMB, ensuring liquidity for future investments[1]. - The company's net assets attributable to shareholders increased by 1.81% from the end of the previous year to CNY 989,361,149.13[19]. - The total assets of the company at the end of the reporting period amounted to 1,180.51 million, with equity attributable to shareholders of the parent company at 989.36 million[54]. - The company reported a significant increase in intangible assets by 395.22% to 60.03 million, mainly due to the acquisition of land use rights[73]. - The company’s total liabilities include significant leasing obligations, with the largest lease being for a warehouse in Guangzhou valued at 1,159.69 million RMB[121]. Sustainability and Environmental Commitment - The management highlighted a commitment to sustainability, aiming to reduce carbon emissions by 15% by 2025[1]. - The company utilizes medical-grade polymer materials for its biological laboratory disposable plastic consumables, emphasizing lightweight, temperature resistance, and pollution resistance[89]. - The implementation of solar photovoltaic power generation systems and central air conditioning water storage systems in some production workshops aims to reduce energy consumption and environmental impact[89]. - The company is committed to reducing carbon emissions through technological innovation and improving production efficiency, which has led to lower product costs[90]. Legal and Compliance - The company has ongoing litigation involving its wholly-owned subsidiary, Baifeier, against Guojij Smart Technology Co., with a claimed advance payment amount of 20,311,900 yuan, which was upheld by the Huangpu Court[111]. - The company has faced no significant changes in audit opinions or bankruptcy restructuring matters during the reporting period[112]. - There are no reported violations or penalties against the company or its executives during the reporting period[114]. Shareholder and Governance - The company has a stock incentive plan in place, which was approved in 2021, but there have been no updates or changes to its implementation[83]. - The company has committed to not providing unfair benefits to other entities or individuals, ensuring the protection of company interests[107]. - The company will ensure independent directors fulfill their responsibilities to protect the overall interests of the company and minority shareholders[108]. - The company has no non-operating fund occupation by controlling shareholders or related parties during the reporting period[110]. Operational Efficiency - The company aims to enhance its R&D capabilities to meet the growing demand for cell therapy products, ensuring compliance with rigorous risk assessment standards[40]. - The company plans to implement a share buyback program worth $20 million to enhance shareholder value[99]. - The company will improve the efficiency of fundraising management and ensure the effective implementation of fundraising projects[100]. - The company will enhance daily operational efficiency and reduce operational costs[100].

Financial Performance - The company's operating revenue for 2021 reached ¥855,658,196.26, representing a 69.80% increase compared to ¥503,933,836.45 in 2020[16]. - The net profit attributable to shareholders for 2021 was ¥171,157,975.38, a 43.38% increase from ¥119,371,464.55 in 2020[16]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥172,997,459.68, up 57.89% from ¥109,567,050.22 in 2020[16]. - The net cash flow from operating activities for 2021 was ¥221,383,765.99, an 18.03% increase from ¥187,566,736.11 in 2020[16]. - The total assets at the end of 2021 amounted to ¥1,180,454,882.67, a 21.73% increase from ¥969,709,074.32 at the end of 2020[16]. - The net assets attributable to shareholders at the end of 2021 were ¥971,819,365.19, reflecting a 21.95% increase from ¥796,893,187.84 at the end of 2020[16]. - The company's basic and diluted earnings per share increased by 40.16% to CNY 1.71 compared to the previous year[17]. - The net profit attributable to shareholders grew by 43.38% to CNY 69.80 million, primarily due to increased sales of disposable plastic consumables in biological laboratories[18]. - The weighted average return on equity rose by 3.05 percentage points to 19.39% compared to the previous year[17]. Dividend and Profit Distribution - The company plans to distribute a cash dividend of 6.00 CNY per 10 shares, totaling 60,000,000 CNY, which represents 35.06% of the net profit attributable to shareholders for 2021[4]. - The profit distribution plan has been approved by the board and awaits shareholder meeting approval[4]. - The cumulative distributable profit for the parent company as of December 31, 2021, was CNY 401.0929 million[156]. - The company plans to distribute at least 10% of the annual distributable profit as dividends, with higher percentages based on the company's development stage and capital expenditure plans[155]. Research and Development - The company applied for 28 patents during the reporting period, including 7 invention patents and 17 utility model patents[27]. - The company achieved a total R&D investment of ¥43,840,335.07, representing an increase of 83.46% compared to the previous year[51]. - R&D investment accounted for 5.12% of total revenue, up from 4.74% in the previous year, marking an increase of 0.38 percentage points[51]. - The number of R&D personnel increased to 150, accounting for 10.48% of the total workforce, up from 6.87% the previous year[69]. - The company is planning to continue increasing R&D investment in response to market demands in cell therapy, biomedicine, infectious disease detection, and vaccine development[27]. Market Expansion and Strategy - The company aims to expand its market share in the biological laboratory consumables industry and penetrate the medical consumables and medical devices sectors[27]. - The company is focused on expanding its market presence and enhancing product development capabilities[10]. - The company plans to enhance its domestic marketing network and expand its market share, aiming for higher penetration rates of domestic products[28]. - The company is exploring overseas brand marketing channels and enhancing its production capabilities through smart manufacturing technologies[28]. - The company aims to strengthen its brand influence and market presence, targeting an increase in domestic market penetration and the establishment of overseas marketing channels within the next three years[122]. Production and Operational Efficiency - The company is focusing on expanding its production capacity to alleviate bottlenecks, with increased demand for disposable plastic consumables in the life sciences sector[28]. - The company has implemented automation in the production of protective masks, establishing a fully automated operation from material feeding to packaging[45]. - The company’s investment in automation technology has led to a significant reduction in manual intervention in production processes, enhancing overall efficiency[58]. - The company has established a flexible customized production capability, allowing for advanced product design solutions and continuous development of high-end consumables, effectively enhancing profitability and core competitiveness[72]. Compliance and Governance - The company has received a standard unqualified audit report from Tianjian Accounting Firm[3]. - The company has not yet achieved profitability since its listing[3]. - The company has detailed potential risks in the annual report, which can be found in the "Management Discussion and Analysis" section[3]. - The company has no violations of decision-making procedures for external guarantees[5]. - The company has not reported any significant changes in its governance structure or independence from its controlling shareholder[125]. Risks and Challenges - The company faces risks in new product market promotion, as new products may take time to achieve large-scale sales, limiting short-term profitability[78]. - Domestic market expansion is challenged by the dominance of imported brands, which may hinder the company's ability to significantly increase its market share[78]. - The company is exposed to overseas sales risks due to geopolitical uncertainties and trade policies, particularly affecting its competitiveness in the U.S. market[79]. - The demand for protective products has declined post-pandemic, leading to potential legal disputes and asset impairment risks due to unsold inventory[80]. - The company is at risk of raw material price fluctuations, as major materials are derived from petroleum, which is subject to price volatility[82]. Environmental and Social Responsibility - The company has implemented measures to reduce carbon emissions, focusing on energy conservation and technological innovation to improve production efficiency[183]. - The company donated 10 million KN95 masks to support pandemic prevention efforts in Guangzhou[186]. - The company has established a quality control management system certified by ISO 9001:2015 and ISO 13485:2016, ensuring no major product quality issues reported[192]. Shareholder and Management Policies - The total remuneration for all directors, supervisors, and senior management personnel at the end of the reporting period amounted to 7.1365 million RMB[138]. - The company has established a compensation and assessment committee to evaluate senior management based on performance standards, continuously improving long-term incentive policies[170]. - The company has a remuneration policy where the compensation for senior management consists of basic salary and year-end bonuses, with the basic salary determined by job level and responsibilities[138]. - The company has committed to maximizing shareholder value while adhering to legal and regulatory requirements for profit distribution[187].

Revenue and Profit - Revenue for Q1 2022 was CNY 190,362,813.69, representing a year-over-year increase of 9.42%[2] - Net profit attributable to shareholders decreased by 14.64% to CNY 41,015,898.04 compared to the same period last year[2] - Basic and diluted earnings per share were both CNY 0.41, down 14.58% year-over-year[2] - Net profit for Q1 2022 was ¥41,015,898.04, a decrease of 14.66% from ¥48,051,641.98 in Q1 2021[14] - Earnings per share for Q1 2022 was ¥0.41, down from ¥0.48 in Q1 2021[15] Expenses and Costs - R&D expenses totaled CNY 9,684,707.76, an increase of 102.82% year-over-year, accounting for 5.09% of revenue[2][5] - Total operating costs for Q1 2022 were ¥143,124,159.20, up from ¥112,539,775.03 in Q1 2021, representing a 27.19% increase[14] - Research and development expenses for Q1 2022 were ¥9,684,707.76, significantly higher than ¥4,775,140.09 in Q1 2021, marking an increase of 102.56%[14] - The company reported a financial expense of ¥1,861,898.50 in Q1 2022, compared to a financial income of ¥1,476,820.70 in Q1 2021[14] Assets and Liabilities - Total assets at the end of Q1 2022 were CNY 1,214,895,768.46, up 2.92% from the end of the previous year[3] - The company's cash and cash equivalents decreased to RMB 202,944,762.76 from RMB 263,468,195.75, representing a decline of about 22.9%[9] - Accounts receivable increased to RMB 150,278,082.51 from RMB 141,090,377.22, showing a growth of approximately 6.5%[9] - Inventory rose to RMB 128,398,777.17 from RMB 123,118,175.57, indicating an increase of about 4.3%[9] - Non-current assets totaled RMB 690,164,465.88, up from RMB 610,492,350.22, marking an increase of approximately 13.1%[10] - The company's total liabilities included accounts payable of RMB 45,596,561.09, down from RMB 67,360,606.60, a decrease of about 32.3%[10] - The company reported a decrease in other payables from RMB 1,822,979.80 to RMB 10,381,334.39, reflecting a significant increase of approximately 471.5%[10] - The company’s total current assets were reported at RMB 524,731,302.58, down from RMB 569,962,532.45, reflecting a decrease of approximately 7.9%[9] - Total liabilities decreased to ¥196,987,467.94 in Q1 2022 from ¥208,635,517.48 in Q1 2021, a reduction of 5.88%[14] - Total equity attributable to shareholders increased to ¥1,017,908,300.52 in Q1 2022 from ¥971,819,365.19 in Q1 2021, an increase of 4.73%[14] Cash Flow - The net cash flow from operating activities was CNY 20,813,635.51, a significant increase from the previous year's negative cash flow[5] - Cash received from sales of goods and services in Q1 2022 was ¥187,269,990.41, compared to ¥138,148,919.16 in Q1 2021, reflecting a growth of 35.51%[17] - Total cash inflow from operating activities reached $212,236,160.54, while cash outflow was $191,422,525.03, resulting in a net increase of $20,813,635.51[18] - Cash flow from investing activities was negative at -$77,178,782.19, compared to -$54,054,106.13 in the same period last year, reflecting increased investment expenditures[18] - Cash flow from financing activities resulted in a net outflow of -$2,469,321.10, a decrease from a net inflow of $3,058,113.22 in the previous year[19] - The company received $3,034,654.16 in tax refunds, contributing to the overall cash inflow from operating activities[18] - Cash paid to employees was $34,266,794.49, an increase from $30,462,781.41 in the previous year, indicating higher personnel costs[18] - Cash paid for taxes amounted to $8,790,573.34, compared to $7,684,658.77 in the same period last year, reflecting an increase in tax obligations[18] Investments and Capital Expenditures - The company has ongoing investments in long-term equity amounting to RMB 49,807,269.40, compared to RMB 30,735,681.62 previously, indicating a growth of approximately 62.1%[10] - The company invested $57,178,782.19 in fixed assets, up from $50,054,106.13 in the previous year, indicating ongoing capital expenditures[18] Shareholder Information - The total number of common shareholders at the end of the reporting period was 4,615[6] - Shareholders' equity attributable to the parent company increased by 4.74% to CNY 1,017,908,300.52[3] Miscellaneous - The company reported non-recurring gains of CNY 1,449,082.21 after tax[4] - The weighted average return on equity decreased by 1.73 percentage points to 4.12%[2] - Deferred income tax liabilities remained stable at ¥1,961,645.33 in both Q1 2022 and Q1 2021[14] - The impact of exchange rate changes on cash and cash equivalents was -$1,688,965.21, compared to -$118,947.16 in the previous year, highlighting currency fluctuations' effect on cash reserves[19]